1. Stohrer M, Goepel M, Kondo A, et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourol Urodyn 1999;18:139.

  2. Abrams P, Cardozo L, Fall M, et al; Standardisation Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-178.

  3. Ku JH. The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int 2006;98(4):739-745.

  4. Rosenblum N. Will the evolution of overactive bladder delivery systems increase patient compliance? Rev Urol 2009;11(2):45-51.

  5. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62(11):1792-1800.

  6. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-
controlled trials. Drugs Aging 2011;28(2):151-160.

  7. Watanabe JH, Campbell JD, Ravelo A, et al. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology 2010;76(4):835-840.

  8. Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil. 2001;80(12):916-922.

  9. Wyndaele JJ, Kovindha A, Madersbacher H, et al. Committee 10 on Neurogenic Bladder and Bowel of the International Consultation on Incontinence 2008-2009. Neurologic urinary incontinence. Neurourol Urodyn 2010;29(1):159-164.

  10. Sussman DO. Overactive bladder: treatment options in primary care medicine. J Am Osteopath Assoc 2007;107(9):379-385.

  11. Stohrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81.

  12. Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Int J Urol 2009;16(2):126-142.

  13. De Ridder DJ, Everaert K, Fernandez LG, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Eur Urol 2005;48(6):991-995.

  14. Lisenmeyer TA, Bodner DR, Creasey GH, et al. Bladder management for adults with spinal cord injury. 
A clinical practice guideline for health-care providers. 
J Spinal Cord Med 2006;29(5):527-573.

  15. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol 2003;43(1):1-5.

  16. Cameron AP. Pharmacologic therapy for the neurogenic bladder. Urol Clin North Am 2010;37(4):495-506.

  17. Kennelly MJ, Devoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol 2008 Summer;10(3):182-191.

  18. Yeaw J, Benner JS, Walt JG, et al. Comparing 
adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15(9):728-740.

  19. Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 2005;59(8):931-937.

  20. D’Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14(3):291-301.

  21. Yamanishi T, Yasuda K, Kamai T, et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol 2004;11:88.

  22. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19(4):380-394.

  23. Chancellor MB, Rivas DA, Staas WE. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc 1994;17(4):165-167.

  24. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998;160(3 pt 1):892-896.

  25. MacDonald R, Monga M, Fink HA, Wilt TJ. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med 2008;31(2):157-165.

  26. Kaufman J, Tyagi V, Anthony M, et al. State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol 2010;12(4):e181-e189.

  27. Yokoyama T, Chancellor MB, Oguma K, et al. Botulinum toxin type A for the treatment of lower urinary tract disorders. Int J Urol 2012;19:202-215.

  28. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49(4):644-650.

  29. US Food and Drug Administration. FDA approves Botox to treat specific form of urinary incontinence. Accessed April 25, 2012.

  30. Albanese A. Terminology for preparations of botulinum neurotoxins. JAMA 2011;305(1):89-90.

  31. Schurch B, de Sèze M, Denys P, et al; for the Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174(1):196-200.

  32. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60(4):742-750.

  33. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and safety study of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. 2011 American Urological Association Annual Meeting. May 2011, Abstract 1515.

  34. Chancellor MB, Patel V, Leng W, et al. OnabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: effects on health related quality of life. American Urological Association Annual Meeting. May 2011, Abstract 1518.

  35. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55(1):100-119.

  36. OnabotulinumtoxinA (Botox) [prescribing information]. Physicians’ Desk Reference. 65th ed. Montvale, NJ:; 2011.

  37. Ellsworth PI, Coyle PK, Esquenazi A, et al. UroToday Int J. 2012;5(suppl 1):art 96. 

  38. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105(9):1276-1282.

  39. O’Leary M, et al. Improvement in health-related quality of life following treatment with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Poster presented at the Society of Urologic Nurses and Associates, 42nd Annual Conference, October 28-31, 2011, 
San Antonio, TX. 

  40. Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007;88:646-652.

  41. Chancellor M, Burks J, Signori M, et al. Development and validation of the urinary incontinence in multiple sclerosis screening tool. International Continence 
Society Annual Meeting, Glasgow, UK. 2011.